DGKα-selective inhibitors are expected to be dual effective drugs (i.e., ideal cancer therapy medicines) because, as described above (Section 3 and Section 4), they simultaneously suppress cancer cell proliferation and boost immune reactions, including anticancer immunity [79] (Figure 3). This evidence concerns the gene DGKA and cancer.